Analyst firms · Raymond James · APLS
Raymond James APLS price target and rating history
Apellis Pharmaceuticals Inc. (APLS) · Health Care
Raymond James rates Apellis Pharmaceuticals Inc. (APLS) Outperform with a $52 price target, as of its latest action on May 9, 2025. It has published 5 rating actions on APLS since August 2021, including 0 upgrades and 1 downgrade. Across 3 firms with a APLS price target in the last 12 months, the median target is $28.
- Current rating
- Outperform
- Price target
- $52
- Median target, all firms
- $28
- Actions on APLS
- 5
Raymond James price target on APLS
Every Raymond James rating on APLS
- May 9, 2025
- Mar 1, 2022
- Jan 11, 2022
- Nov 9, 2021
- Aug 10, 2021
How other firms rate APLS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Roth Capital | Buy | $31 | Mar 13, 2026 |
| Barclays | Equal Weight | $24 | Jan 28, 2026 |
| BofA Securities | Buy | $28 | Jan 21, 2026 |
Questions about Raymond James and APLS
- What is Raymond James's price target for APLS?
- Raymond James's latest stated price target for Apellis Pharmaceuticals Inc. (APLS) is $52, from its action on May 9, 2025.
- What is Raymond James's rating on APLS?
- Raymond James rates APLS Outperform, a bullish rating, as of May 9, 2025.
- When did Raymond James last change its view on APLS?
- On May 9, 2025, Raymond James downgrades to Outperform from Strong Buy, price target $52.
- How does Raymond James's APLS target compare with other analysts?
- Across 3 firms with a APLS price target in the last 12 months, the median target is $28.
More APLS rating histories
All Raymond James ratingsAPLS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.